[Sotahexal pharmacodynamics in patients with ischemic heart disease].
Therapeutic and prophylactic antiarrhythmic efficacy of sotalol hydrochloride (Sotahexal, "Hexal", Germany) and its effects in intracardiac hemodynamics and ECG parameters were evaluated in 95 patients with ischemic heart disease (IHD). The highest response to the drug was observed in ventricular extrasystoles, arterial flutter and fibrillation. Acute episodes of arrhythmia are managed by bolus administration of Sotahexal [correction of Hexal]. In this case greater risk of side effects exists. It is desirable to decide on the drug dose, mode of administration on the individual basis with due consideration of the risks and dangers which could be avoided in case of adequate instrumental control.
Dorofeeva
E Iu
EIu
Gorshkov
V A
VA
Chestukhin
V V
VV
Lyskovtsev
V V
VV
Bezprozvannyĭ
A B
AB
Avdeĭchuk
E D
ED
Kesarev
G V
GV
Lazutina
O M
OM
Nesvetov
V N
VN
Radzevich
A E
AE
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control; D002415:Cats; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D013015:Sotalol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D013607:Tablets
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D013607:Tablets; D013015:Sotalol